Study ID: S1400-F
Phase 2/3 biomarker-driven master protocol for previously treated squamous cell lung cancer (LUNG-MAP)
This treatment trial, which is part of the LUNG-MAP larger clinical study, is for patients who have been diagnosed with certain types of squamous cell lung cancer. Participants will receive two medications intravenously:
- Durvalumab, an FDA-approved immunotherapy for cancer
- Tremelimumab, a human monoclonal antibody that is known as an immune checkpoint blocker
Patients will undergo intravenous infusion of both drugs on day 1 for 4 courses, and then tremelimumab alone on day 1 of course 5 and subsequent courses unless disease progresses or toxicity occurs. Courses repeat every 28 days.
- Must have been diagnosed with squamous cell lung cancer
- Must be willing to undergo intravenous treatment